Belantamab mafodotin

MISSISSAUGA, ON , Sept. 22, 2026 /CNW/ -- GSK Canada announced today that it has completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA), resulting in a Letter of Intent (LOI) for Blenrep (belantamab mafodotin for injection) for the treatment of adult patients with relapsed or refractory multiple myeloma. The LOI with the pCPA is an important step towards securing public drug plan coverage for Blenrep across Canada. Following the finalization of funding agreements with each of the provinces and territories, eligible patients will gain publicly funded access to Blenrep as a new treatment option for relapsed or refractory multiple myeloma. "This agreement moves us closer to ensuring that eligible patients can access new treatment options for a disease that often relapses and requires multiple lines of therapy," said Tina Graves, General Manager, GSK Canada. "Our priority now is to work with provinces and territories to translate the pCPA outcome into access for patients. Multiple myeloma has seen great innovation in recent years, yet there remains a need for effective, practical treatments that are accessible across all treatment settings and that help reduce the day-to-day impact of care on patients and their families." "People affected by this rare and complex blood cancer often face repeated rounds of treatment, ongoing symptoms and frequent hospital visits, which can be challenging for patients in urban settings as well as those in rural and remote communities. Public coverage for new treatment options such as Blenrep has the potential to ease some of that burden and give patients and families greater confidence that the care they need will be within reach over the long term," said Martine Elias, CEO, Myeloma Canada. "We're pleased to see two successful negotiations for Blenrep for adult patients with multiple myeloma who have received at least one prior therapy," said Mauro Chies, Chief Executive Officer, pCPA. "Drug price negotiations are opportunities for strong collaboration, and both the pCPA and GSK can share satisfaction in knowing we are supporting timely public coverage of new drugs for Canadians who need them." The LOI does not itself constitute a reimbursement decision. Final coverage will be determined by individual public drug plans in line with their own review processes and timelines. The successful conclusion of pCPA negotiations underscores GSK Canada's commitment to advancing innovation in hematology-oncology and improving outcomes for people living with multiple myeloma. Blenrep is the first and only anti-BCMA (B-cell maturation antigen) antibody-drug conjugate (ADC) for multiple myeloma. Blenrep 's mechanism of action is distinct from other therapies, and it is approved in two combination regimens that can be administered to a broad range of patient types as early as first relapse without complex pre-administration care or hospitalization. Blenrep was approved in two different combination regimens by Health Canada in July 2025 . About multiple myeloma Multiple myeloma is the third most common blood cancer globally and is generally considered treatable but not curable. 1,2 There are approximately more than 180,000 new cases of multiple myeloma diagnosed globally each year. 3 Multiple myeloma is a significant concern in Canada, where, in 2025 alone, 4,300 people were diagnosed with the disease. 4 Research into new therapies is needed as multiple myeloma commonly becomes refractory to available treatments. 1 About Blenrep Blenrep is an antibody-drug conjugate (ADC) comprised of a humanized anti-BCMA monoclonal antibody conjugated to the cytotoxic agent monomethyl auristatin F. In Canada, Blenrep (belantamab mafodotin for injection) is indicated for the treatment of adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy. Specifically, Blenrep is indicated: - in combination with bortezomib and dexamethasone (BVd), in adult patients who have received at least one prior therapy; and - in combination with pomalidomide and dexamethasone (BPd), in adult patients who have received at least one prior line of therapy, including lenalidomide. Please consult the Product Monograph at for complete safety information. The Product Monograph is also available by calling 1-800-387-7374. GSK in Oncology Our ambition in oncology is to help increase overall quality of life, maximize survival, and change the course of disease, expanding from our current focus on blood and women's cancers into lung and gastrointestinal cancers, as well as other solid tumours. About GSK GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at . Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2025, and GSK's Q2 Results for 2026. References 1. Sung H, Ferlay J, Siegel R, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660. 2. Kazandjian D. Multiple myeloma epidemiology and survival: A unique malignancy. Semin Oncol. 2016;43(6):676–681.doi: 10.1053/j.seminoncol.2016.11.004. 3. Global Cancer Observatory. International Agency for Research on Cancer. World Health Organization. Multiple Myeloma fact sheet. Available at: Accessed 5 March 2025. 4. Multiple myeloma statistics. Canadian Cancer Society. Available at: Accessed 6 May 2026. SOURCE GlaxoSmithKline Inc.

GSK said Tuesday it will acquire a potentially best-in-class trispecific T cell-engager (TCE) from Chimagen Biosciences, in a deal worth as much as $750 million, with plans to develop and commercialise the unnamed asset for multiple myeloma."The agreement complements our existing portfolio in multiple myeloma, adding a new potential option to address the different needs of patients facing this complex disease," said Hesham Abdullah, GSK's global head of oncology R&D. GSK currently markets the BCMA-directed antibody–drug conjugate Blenrep (belantamab mafodotin) for relapsed or refractory myeloma.Despite TCEs having shown transformative efficacy in myeloma, tolerability has often been a challenge. Chimagen’s trispecific is designed to counter this by engaging T cells while simultaneously targeting two validated tumour-associated antigens — thereby delivering deeper and more durable responses, with potential for broader and earlier use in the condition.As per the agreement's terms, GSK will secure full global rights to the TCE programme, potentially kicking off Phase I studies next year. The UK drugmaker will pay Chimagen an undisclosed upfront fee, with the latter also eligible for additional milestone payments. The latest deal builds on a 2024 alliance between the companies, wherein the Shanghai-based biotech outlicensed to GSK a TCE candidate targeting both CD19 and CD20, dubbed CMG1A46, currently in early-stage testing for B-cell malignancies and B-cell-dependent autoimmune disorders.